Union Therapeutics starts phase II trial of nasal spray for Covid-19 patients

Biotech company Union Therapeutics is testing its candidate niclosamide as a nasal spray for patients infected with Covid-19 who are either asymptomatic or mildly symptomatic in a phase II study.
Photo: Union Therapeutics / PR
Photo: Union Therapeutics / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

The Danish biotech company Union Therapeutics has enrolled the first patient in its phase II trial of drug candidate niclosamide as a treatment for Covid-19 patients, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading